Castle Biosciences | GenomeWeb

Castle Biosciences

The Medicare contractor is proposing to not cover Vectra DA, but to extend coverage for Prolaris, Xpresys, and DecisionDx-UM under specific circumstances.

The company's new $14 million facility refinances its original $6 million loan, and adds capital for new growth.

The first tranche of the targeted $20 million financing round will be used to accelerate adoption of the company's melanoma test.

The financing will go toward commercial and clinical activities to increase adoption of the company's DecisionDx-Melanoma test.

The study demonstrated that the company's DecisionDx-Melanoma assay better predicts the risk of metastasis in patients with localized disease than clinical staging alone.

Survey results reflect strong penetration of Castle Biosciences' uveal melanoma test among specialists as the company plans a future focus on more prevalent diseases.

NEW YORK (GenomeWeb) – Cancer molecular diagnostics firm Castle Biosciences today said that it raised $11.8 million in a Series E financing round.

Originally published May 6. NEW YORK (GenomeWeb) – Castle Biosciences presented data from two validation studies involving its DecisionDx - Mesothelioma molecular test at the American Association for Thoracic Surgery annual meeting.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.